Glaxosmithkline PLC, 10% Owner at Theravance Biopharma, Inc. (TBPH), bought 1,301,015 shares at $23.03 ($30.0M) on 2016-03-14, disclosed to the SEC on 2016-03-15.
Open-market purchase of $30.0M TBPH by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| Filing → |
| INVA | SELL | 2021-05-24 | $392.1M | — | Filing → |
| DBTX | BUY | 2021-02-19 | $2.7M | — | Filing → |
| BCYC | SELL | 2020-09-18 | $151K | — | Filing → |